Induction or exacerbation of psoriatic lesions during anti-TNF-α therapy for inflammatory bowel disease: A systematic literature review based on 222 cases

dc.contributorUniversidade Estadual Paulista (UNESP)
dc.creatorDenadai, Rafael
dc.creatorTeixeira, Fábio Vieira
dc.creatorSteinwurz, Flavio
dc.creatorRomiti, Ricardo
dc.creatorSaad-Hossne, Rogério
dc.date2014-05-27T11:27:28Z
dc.date2016-10-25T18:40:54Z
dc.date2014-05-27T11:27:28Z
dc.date2016-10-25T18:40:54Z
dc.date2013-01-01
dc.date.accessioned2017-04-06T02:07:06Z
dc.date.available2017-04-06T02:07:06Z
dc.identifierJournal of Crohn's and Colitis, v. 7, n. 7, p. 517-524, 2013.
dc.identifier1873-9946
dc.identifier1876-4479
dc.identifierhttp://hdl.handle.net/11449/74167
dc.identifierhttp://acervodigital.unesp.br/handle/11449/74167
dc.identifier10.1016/j.crohns.2012.08.007
dc.identifierWOS:000321079500001
dc.identifier2-s2.0-84878657106.pdf
dc.identifier2-s2.0-84878657106
dc.identifierhttp://dx.doi.org/10.1016/j.crohns.2012.08.007
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/894940
dc.descriptionBackground: Paradoxical cases of psoriatic lesions induced or exacerbated by anti-tumor necrosis factor (TNF)-α therapy have been reported more frequently in recent years, but data related to inflammatory bowel disease (IBD) are rare. A systematic literature review was performed to provide information about this adverse effect in patients with IBD who receive anti-TNF therapy. Methods: Published studies were identified by a search of Medline, Embase, Cochrane, SciELO, and LILACS databases. Results: A total of 47 studies (222 patients) fulfilled the inclusion criteria and were selected for analysis. Clinical and therapeutic aspects varied considerably among these reports. Of the 222 patients, 78.38% were diagnosed with Crohn's disease, and 48.20% were female. The mean patient age was 26.50. years, and 70.72% of patients had no history of psoriasis. Patients developed psoriasiform lesions (55.86%) more often than other types of psoriatic lesions, and infliximab was the anti-TNF-α therapy that caused the cutaneous reaction in most patients (69.37%). Complete remission of cutaneous lesions was observed in 63.96% of the cases. Conclusions: We found that psoriatic lesions occurred predominantly in adult patients with Crohn's disease who received infliximab and had no previous history of psoriasis. Most patients can be managed conservatively without discontinuing anti-TNF-α therapy. © 2012 European Crohn's and Colitis Organisation.
dc.languageeng
dc.relationJournal of Crohn's and Colitis
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAdalimumab;
dc.subjectBiological therapy
dc.subjectCertolizumab;
dc.subjectInflammatory bowel disease;
dc.subjectInfliximab;
dc.subjectPsoriasis;
dc.subjectadalimumab
dc.subjectazathioprine
dc.subjectcertolizumab pegol
dc.subjectcorticosteroid
dc.subjectetanercept
dc.subjectinfliximab
dc.subjectmesalazine
dc.subjectmethotrexate
dc.subjecttumor necrosis factor alpha inhibitor
dc.subjectCrohn disease
dc.subjectdrug withdrawal
dc.subjectenteritis
dc.subjecthuman
dc.subjectpriority journal
dc.subjectpsoriasis
dc.subjectpustulosis palmoplantaris
dc.subjectreview
dc.subjectskin manifestation
dc.subjectspondylarthritis
dc.subjectsystematic review
dc.titleInduction or exacerbation of psoriatic lesions during anti-TNF-α therapy for inflammatory bowel disease: A systematic literature review based on 222 cases
dc.typeOtro


Este ítem pertenece a la siguiente institución